文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

磷脂酶 A2 酶在银屑病和毛发红糠疹中代表了一个共同的致病途径。

Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.

机构信息

Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shannxi, China.

Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.

出版信息

JCI Insight. 2021 Oct 22;6(20):e151911. doi: 10.1172/jci.insight.151911.


DOI:10.1172/jci.insight.151911
PMID:34491907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8564909/
Abstract

Altered epidermal differentiation along with increased keratinocyte proliferation is a characteristic feature of psoriasis and pityriasis rubra pilaris (PRP). However, despite this large degree of overlapping clinical and histologic features, the molecular signatures these skin disorders share are unknown. Using global transcriptomic profiling, we demonstrate that plaque psoriasis and PRP skin lesions have high overlap, with all differentially expressed genes in PRP relative to normal skin having complete overlap with those in psoriasis. The major common pathway shared between psoriasis and PRP involves the phospholipases PLA2G2F, PLA2G4D, and PLA2G4E, which were found to be primarily expressed in the epidermis. Gene silencing each of the 3 PLA2s led to reduction in immune responses and epidermal thickness both in vitro and in vivo in a mouse model of psoriasis, establishing their proinflammatory roles. Lipidomic analyses demonstrated that PLA2s affect mobilization of a phospholipid-eicosanoid pool, which is altered in psoriatic lesions and functions to promote immune responses in keratinocytes. Taken together, our results highlight the important role of PLA2s as regulators of epidermal barrier homeostasis and inflammation, identify PLA2s as a shared pathogenic mechanism between PRP and psoriasis, and as potential therapeutic targets for both diseases.

摘要

表皮分化改变和角质形成细胞增殖增加是银屑病和毛发红糠疹(PRP)的特征。然而,尽管这两种疾病具有很大程度的临床和组织学特征重叠,但这些皮肤疾病的分子特征尚不清楚。通过全转录组分析,我们证明斑块状银屑病和 PRP 皮肤病变具有高度重叠性,PRP 相对于正常皮肤的所有差异表达基因与银屑病中的完全重叠。银屑病和 PRP 之间共享的主要共同途径涉及磷脂酶 PLA2G2F、PLA2G4D 和 PLA2G4E,它们主要在表皮中表达。在体外和体内银屑病小鼠模型中,对这 3 种 PLA2 进行基因沉默,导致免疫反应和表皮厚度减少,从而确立了它们的促炎作用。脂质组学分析表明,PLA2 影响磷脂 - 类二十烷酸库的动员,银屑病病变中该库发生改变,可促进角质形成细胞中的免疫反应。总之,我们的研究结果强调了 PLA2 作为表皮屏障稳态和炎症调节因子的重要作用,确定 PLA2 是 PRP 和银屑病之间的共同致病机制,并可能成为这两种疾病的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/0df4453bf679/jciinsight-6-151911-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/1d23ec336a6a/jciinsight-6-151911-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/a04b370e0921/jciinsight-6-151911-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/f96f64df0bba/jciinsight-6-151911-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/023a3fe748c9/jciinsight-6-151911-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/5a885aba479d/jciinsight-6-151911-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/552f3c98a392/jciinsight-6-151911-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/0df4453bf679/jciinsight-6-151911-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/1d23ec336a6a/jciinsight-6-151911-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/a04b370e0921/jciinsight-6-151911-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/f96f64df0bba/jciinsight-6-151911-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/023a3fe748c9/jciinsight-6-151911-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/5a885aba479d/jciinsight-6-151911-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/552f3c98a392/jciinsight-6-151911-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1af/8564909/0df4453bf679/jciinsight-6-151911-g007.jpg

相似文献

[1]
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.

JCI Insight. 2021-10-22

[2]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2017-12-22

[3]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[4]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[5]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2022-5-23

[6]
Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study.

Br J Dermatol. 2024-7-16

[7]
Low-grade systemic inflammation is associated with risk of psoriasis in a general population study of more than 100 000 individuals.

Br J Dermatol. 2025-7-17

[8]
The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull. 2024-7-8

[9]
A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists.

J Eur Acad Dermatol Venereol. 2012-2-10

[10]
Anti-TNF agents for paediatric psoriasis.

Cochrane Database Syst Rev. 2015-11-24

引用本文的文献

[1]
Ponatinib-induced psoriasis treated with tildrakizumab.

JAAD Case Rep. 2025-5-28

[2]
CD1a and Lipids as Mediators of T Cell Activation in the Skin.

J Invest Dermatol. 2025-5-3

[3]
Recent Progress in -Acylethanolamine Research: Biological Functions and Metabolism Regulated by Two Distinct -Acyltransferases: cPLAε and PLAAT Enzymes.

Int J Mol Sci. 2025-4-3

[4]
Uncommon Presentation of Pityriasis Rubra Pilaris of the Scalp: Clinical, Trichoscopic, and Histopathologic Features and Review of the Literature.

Medicina (Kaunas). 2024-11-8

[5]
Analysis of key pathways and genes in nodal structure on rat skin surface using gene ontology and KEGG pathway.

Genes Genomics. 2025-1

[6]
Phospholipase A2 group IVD mediates the transacylation of glycerophospholipids and acylglycerols.

J Lipid Res. 2024-12

[7]
Bioinformatics Analysis of Differentially Expressed Genes in Carpal Tunnel Syndrome Using RNA Sequencing.

Iran J Public Health. 2024-8

[8]
Establishment of a Mouse Model for Porokeratosis Due to Mevalonate Diphosphate Decarboxylase Deficiency.

Skin Res Technol. 2024-9

[9]
Dermal Delivery of (L.) Loaded Nanogel: Formulation to Preclinical Psoriasis Assessment.

Recent Adv Drug Deliv Formul. 2024

[10]
Selenomethionine in gelatin methacryloyl hydrogels: Modulating ferroptosis to attenuate skin aging.

Bioact Mater. 2024-2-21

本文引用的文献

[1]
Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels.

J Invest Dermatol. 2022-1

[2]
Psoriasis.

Lancet. 2021-4-3

[3]
Response to: 'Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab'.

Br J Dermatol. 2021-7

[4]
Resolvin D1 Attenuates Innate Immune Reactions in Experimental Subarachnoid Hemorrhage Rat Model.

Mol Neurobiol. 2021-5

[5]
Updating Phospholipase A Biology.

Biomolecules. 2020-10-19

[6]
cPLAα Enzyme Inhibition Attenuates Inflammation and Keratinocyte Proliferation.

Biomolecules. 2020-10-2

[7]
Treatment of pityriasis rubra pilaris: a case series of 28 patients.

Eur J Dermatol. 2020-10-1

[8]
Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin.

J Allergy Clin Immunol. 2020-7

[9]
Phospholipase A Inhibitor-Loaded Phospholipid Micelles Abolish Neuropathic Pain.

ACS Nano. 2020-7-28

[10]
Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.

JAMA Dermatol. 2020-6-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索